Muraymycin A1 (MA1), a newly identified natural product inhibitor of DPAGT1, holds strong potential to improve human health and treat diseases associated with prolonged ER stress, including inflammation- and immune-related disorders, cardiovascular disease, metabolic syndromes, and cancer. Here, DPAGT1 is linked to metabolic syndrome.